TY - JOUR
T1 - High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer
T2 - current status, future trends.
AU - Montemurro, F.
AU - Ueno, N. T.
AU - Rondón, G.
AU - Aglietta, M.
AU - Champlin, R. E.
PY - 2000/10
Y1 - 2000/10
N2 - High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT) has been extensively studied as a potential treatment for breast cancer. A literature search of MEDLINE from January 1990 through December 1999 identified 497 published full papers. Of these articles, 120 reported the results of clinical trials, 78 were reviews, and 299 reported on issues related to the technology of peripheral stem cells, supportive care, and toxicity. The phase II data must be interpreted with caution, as it is subject to selection bias; transplant recipients tended to be younger, rigorously staged, and selected to be chemotherapy responsive. There continues to be controversy regarding the role of high-dose therapy in this disease. Only a few fully published randomized trials are available; these studies were powered only to detect large differences in survival and no benefit was shown. Several large controlled trials are either in progress or are too early for definitive analysis. This review analyzes the current literature on HDC/HSCT for breast cancer, identifying prognostic factors and discussing ongoing research designed to improve antitumor effects.
AB - High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT) has been extensively studied as a potential treatment for breast cancer. A literature search of MEDLINE from January 1990 through December 1999 identified 497 published full papers. Of these articles, 120 reported the results of clinical trials, 78 were reviews, and 299 reported on issues related to the technology of peripheral stem cells, supportive care, and toxicity. The phase II data must be interpreted with caution, as it is subject to selection bias; transplant recipients tended to be younger, rigorously staged, and selected to be chemotherapy responsive. There continues to be controversy regarding the role of high-dose therapy in this disease. Only a few fully published randomized trials are available; these studies were powered only to detect large differences in survival and no benefit was shown. Several large controlled trials are either in progress or are too early for definitive analysis. This review analyzes the current literature on HDC/HSCT for breast cancer, identifying prognostic factors and discussing ongoing research designed to improve antitumor effects.
UR - http://www.scopus.com/inward/record.url?scp=0034309080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034309080&partnerID=8YFLogxK
U2 - 10.3816/cbc.2000.n.016
DO - 10.3816/cbc.2000.n.016
M3 - Review article
C2 - 11899644
AN - SCOPUS:0034309080
SN - 1526-8209
VL - 1
SP - 197-209; discussion 210
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 3
ER -